CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Eslicarbazepine acetate

Last Updated: August 15, 2014
Result type: Reports
Project Number: SR0391-000
Product Line: Reimbursement Review

Generic Name: Eslicarbazepine acetate

Brand Name: Aptiom

Manufacturer: Sunovion Pharmaceuticals Canada Inc.

Therapeutic Area: Epilepsy, partial-onset seizures

Indications: Epilepsy, partial-onset seizures

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 16, 2015

Recommendation Type: List with criteria/condition